ClinicalTrials.gg
CompletedNCT01449929FLAMINGOUpdated Jan 16, 2018Results posted

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

A Phase 3 interventional study of dolutegravir 50 mg OAD and darunavir 800mg OAD in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 66 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and background NRTI selection. The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.

Read the detailed description

ING114915 is a Phase IIIb randomized, open-label, active-controlled, multicentre, parallel group, fully-powered non-inferiority study. The study will be conducted in approximately 468 HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 to receive DTG 50 mg once daily (approximately 234 subjects) or DRV/r 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC). The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.

Subjects who fulfil eligibility requirements will be randomized 1:1 to receive DTG 50 mg once daily or DRV/r 800 mg/100 mg once daily. In order to achieve balance across the two treatment groups of the study, randomization will be stratified by: screening plasma HIV-1 RNA >/ 100,000 copies/mL (c/mL) or > 100,000 c/mL and background dual NRTI (ABC/3TC or TDF/FTC) The DTG and DRV/r doses will be administered in an open-label fashion throughout the study.

Subjects randomized to receive DTG and who successfully complete 96 weeks of treatment will continue to have access to DTG until either it is locally approved and commercially available, the patient no longer derives clinical benefit, the patient meets a protocol-defined reason for discontinuation or until development of DTG is terminated. Subjects randomized to the DRV/r arm will receive DRV/r through their Week 96 visit, after which they will be discontinued from the study and will need to make alternative arrangements to access antiretroviral medication. All subjects will receive background dual-NRTI therapy through their Week 96 visit.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • ritonavir
  • HIV
  • HAART
  • darunavir
  • antiretroviral
  • dolutegravir
  • GSK1349572
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 488 is above the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-, (2) child bearing potential with negative pregnancy test at screening and Day 1 and agrees to use protocol-specified methods of while on study.
  • HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 1000copies/mL
  • Antiretroviral-naïve (less than or equal to 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
  • Signed and dated written is obtained from the subject or the subject's legal representative prior to screening

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Any evidence of an active Centers for Disease and Prevention Control (CDC) Category C disease [CDC, 1993], except cutaneous Kaposi's sarcoma not requiring systemic therapy
  • Subjects with moderate to severe hepatic impairment (Class B or C) as determined by classification
  • Anticipated need for virus (HCV) therapy during the study
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 in vitro within 28 days of first dose of product
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of investigational product
  • Any evidence of primary viral resistance based on the presence of any major resistance-associated mutation [IAS-USA, 2010] in the Screening result or, if known, any historical resistance test result
  • Any verified Grade 4 laboratory abnormality. Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound is exclusionary
  • (ALT) greater than 5 times the
  • ALT greater than 3 times the upper limit of normal and greater than or equal to 1.5 times the upper limit of normal (with greater than 35% direct bilirubin)
  • Subject has of less than 50 mL/min via Cockroft-Gault method
  • Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    dolutegravir 50mg once daily (OAD)

    in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD

    Drug: dolutegravir 50 mg OAD

  • Active comparator
    darunavir 800mg OAD in combination with ritonavir 100mg OAD

    in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD

    Drug: darunavir 800mg OAD · Drug: ritonavir 100mg OAD

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48

    Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product

    Time frame: Week 48

Secondary outcomes

  1. Time to Virologic Suppression (<50 Copies/mL) Through Week 48

    The time to viral suppression (i.e. first viral load value \<50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.

    Time frame: From Baseline through Week 48

  2. Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 48

    The percentage of participants with Plasma HIV-1 RNA \<400 c/mL at Week 48 was assessed MSDF, as codified by the FDA "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).

    Time frame: Week 48

  3. Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48

    Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 36 and 48

  4. Change From Baseline in CD4+ and CD8+ Cell Counts

    Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 36 and 48 for CD4+ and Baseline and Weeks 4, 12, 24 and 48 for CD8+

  5. Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48

    The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

    Time frame: Week 48

  6. Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48

    Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment\*visit interaction and Baseline LDL cholesterol\*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.

    Time frame: From Baseline through Week 48

  7. Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48

    Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.

    Time frame: From Baseline through Week 48

  8. Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities

    Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.

    Time frame: From Baseline through Week 48

  9. Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)

    An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA \>200 c/mL \>=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.

    Time frame: Baseline until PDVF up to Week 48

  10. Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48

    SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participant's quality of life over that period.

    Time frame: Baseline, Week 4, Week 24, and Week 48

  11. Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48

    The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24, and Week 48

  12. Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48

    The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline, Week 24, and Week 48

  13. Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48

    Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

    Time frame: Week 4, Week 24, and Week 48

  14. Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48

    Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

    Time frame: Week 4, Week 24, and Week 48

  15. Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48

    Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

    Time frame: Week 4, Week 24, and Week 48

07

Results

Posted Mar 27, 2014

Participant flow

This was a 2 sequential treatment period study. In first period (Randomization phase) participants received either dolutegravir (DTG) 50 milligram (mg) or darunavir (DRV) 800 mg with ritonavir (RTV) 100 mg once daily (QD) for 96 weeks. DTG participants who completed 96 Weeks of DTG then continued to receive DTG 50 mg in Extension phase.

Randomization Phase 96 Week
Participant flow — Randomization Phase 96 Week
MilestoneDTG 50 mg QDDRV 800 mg + RTV 100 mg QDExtension DTG 50 mg
Started2422420
Completed2091890
Not completed33530
Withdrew: Adverse event5130
Withdrew: Lack of efficacy340
Withdrew: Protocol violation560
Withdrew: Protocol-defined stopping criteria100
Withdrew: Lost to follow-up15180
Withdrew: Withdrawal by subject280
Withdrew: Physician decision230
Withdrew: Other: study closed/terminated010
Extension Phase Approximately 3 Years
Participant flow — Extension Phase Approximately 3 Years
MilestoneDTG 50 mg QDDRV 800 mg + RTV 100 mg QDExtension DTG 50 mg
Started00123
Completed00115
Not completed008
Withdrew: Adverse event002
Withdrew: Lack of efficacy002
Withdrew: Lost to follow-up004

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48

Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48
Percentage of participantsDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 489083
Statistical analysis
  • DTG 50 mg QD vs DRV 800 mg + RTV 100 mg QD · Cochran-Mantel-Haenszel · p = 0.025 (P-value is for test of superiority.) · Difference in percentage: 7.1 · 95% CI 0.9 to 13.2Analysis was adjusted for the Baseline (BL) stratification factors: Baseline plasma HIV-1 RNA (\<=100,000 c/mL vs \>100,000 c/mL) and Baseline background dual NRTI therapy (ABC/3TC vs TDF/FTC).
SecondaryTime to Virologic Suppression (<50 Copies/mL) Through Week 48

The time to viral suppression (i.e. first viral load value \<50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.

Time frame:
From Baseline through Week 48
Reported as:
Median · Days
Time to Virologic Suppression (<50 Copies/mL) Through Week 48
DaysDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Time to Virologic Suppression (<50 Copies/mL) Through Week 4828.0 (NA to NA)85.0 (84.0 to 108.0)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 48

The percentage of participants with Plasma HIV-1 RNA \<400 c/mL at Week 48 was assessed MSDF, as codified by the FDA "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 48
Percentage of participantsDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 489287
SecondaryChange From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48

Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 24, 36 and 48
Reported as:
Mean · Log10 copies per mL
Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48
Log10 copies per mLDTG 50 mg ODDRV 800 mg + RTV 100 mg OD
Week 4, n=238, 235-2.80 ± 0.625-2.01 ± 0.454
Week 8, n=237, 236-2.86 ± 0.649-2.40 ± 0.524
Week 12, n=234, 227-2.88 ± 0.653-2.61 ± 0.537
Week 16, n=229, 228-2.86 ± 0.691-2.71 ± 0.618
Week 24, n=234, 227-2.86 ± 0.765-2.83 ± 0.663
Week 36, n=232, 218-2.87 ± 0.715-2.85 ± 0.683
Week 48, n=227, 212-2.89 ± 0.739-2.86 ± 0.663
SecondaryChange From Baseline in CD4+ and CD8+ Cell Counts

Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 36 and 48 for CD4+ and Baseline and Weeks 4, 12, 24 and 48 for CD8+
Reported as:
Mean · Cells per millimeters cubed (cells/mm^3)
Change From Baseline in CD4+ and CD8+ Cell Counts
Cells per millimeters cubed (cells/mm^3)DTG 50 mg QDDRV 800 mg + RTV 100 mg QD
CD4+ cell count, Week 4, n=237, 23680.1 ± 101.3675.6 ± 124.36
CD4+ cell count, Week 8, n=236, 236126.9 ± 124.13118.8 ± 142.54
CD4+ cell count, Week 12, n=234, 228135.2 ± 120.03131.8 ± 143.88
CD4+ cell count, Week 16, n=227, 227156.8 ± 146.60146.1 ± 166.08
CD4+ cell count, Week 24, n=233, 227165.1 ± 145.85164.3 ± 180.00
CD4+ cell count, Week 36, n=232, 218206.1 ± 159.06186.5 ± 183.61
CD4+ cell count, Week 48, n=227, 212243.8 ± 180.68215.4 ± 177.26
CD8+ cell count, Week 4, n=235, 235-47.4 ± 276.01-3.7 ± 375.94
CD8+ cell count, Week 12, n=231, 227-42.0 ± 343.81-68.9 ± 373.38
CD8+ cell count, Week 24, n=231, 224-108.0 ± 350.03-132.9 ± 389.70
CD8+ cell count, Week 48, n=224, 210-109.5 ± 360.94-162.1 ± 421.07
SecondaryNumber of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48

The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48
ParticipantsDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 4800
SecondaryChange From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48

Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment\*visit interaction and Baseline LDL cholesterol\*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.

Time frame:
From Baseline through Week 48
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48
Millimoles per liter (mmol/L)DTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 480.07 ± 0.0410.37 ± 0.041
SecondaryPercentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48

Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.

Time frame:
From Baseline through Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48
Percentage of ParticipantsDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 4827
SecondaryNumber of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities

Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.

Time frame:
From Baseline through Week 48
Reported as:
Number · Participants
Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities
ParticipantsDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Alanine Amino Transferase, G321
Alanine Amino Transferase, G413
Aspartate Amino Transferase, G363
Aspartate Amino Transferase, G420
Cholesterol, G303
Creatine Kinase, G385
Creatine Kinase, G484
Hyperglycaemia, G312
Hypoglycaemia, G301
LDL Cholesterol, G326
Lipase, G355
Lipase, G420
Phosphorus, inorganic, G377
Total Bilirubin, G310
Triglycerides, G312
Triglycerides, G401
Hemoglobin, G310
Hemoglobin, G410
Platelet count, G401
Total Neutrophils, G350
Total Neutrophils, G431
SecondaryNumber of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)

An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA \>200 c/mL \>=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.

Time frame:
Baseline until PDVF up to Week 48
Reported as:
Number · Participants
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)
ParticipantsDTG 50 mg ODDRV 800 mg + RTV 100 mg OD
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)00
SecondaryChange From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48

SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participant's quality of life over that period.

Time frame:
Baseline, Week 4, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 4, n=218, 210-3.20 ± 0.56-2.19 ± 0.56
Week 24, n=222, 214-2.71 ± 0.64-1.65 ± 0.65
Week 48, n= 222, 215-2.46 ± 0.68-0.77 ± 0.69
SecondaryChange From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48

The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 24, n=217, 2130.00 ± 0.0120.02 ± 0.012
Week 48, n=224, 2170.01 ± 0.0120.01 ± 0.012
SecondaryChange From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48

The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 24, n=221, 2164.95 ± 0.8855.96 ± 0.895
Week 48, n=224, 2205.78 ± 0.7626.95 ± 0.769
SecondaryHuman Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48

Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

Time frame:
Week 4, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 4, n=206, 19254.1 ± 6.4352.4 ± 7.94
Week 24, n= 211, 20056.1 ± 5.1654.3 ± 6.94
Week 48, n=212, 20156.1 ± 4.6054.5 ± 6.78
SecondaryHuman Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48

Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

Time frame:
Week 4, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 4, n=202, 19026.7 ± 3.6125.8 ± 4.48
Week 24, n=210, 19927.5 ± 3.1626.6 ± 4.11
Week 48, n=211, 20127.6 ± 3.0026.6 ± 4.11
SecondaryHuman Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48

Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.

Time frame:
Week 4, Week 24, and Week 48
Reported as:
Mean · Scores on a scale
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48
Scores on a scaleDTG 50 mg QDDRV 800 mg + RTV 100 mg QD
Week 4, n=204, 1905.6 ± 0.715.2 ± 1.11
Week 24, n=211, 200,5.6 ± 0.645.4 ± 1.01
Week 48, n=212, 2015.7 ± 0.625.4 ± 1.02

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the available safety data from the start of the study medication up to end of study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG 50mg QD1/242 (0.4%)36/242 (14.9%)221/242 (91.3%)
DRV 800 mg + RTV 100 mg QD0/242 (0%)21/242 (8.7%)214/242 (88.4%)
Extension DTG 50 mg0/123 (0%)4/123 (3.3%)52/123 (42.3%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventDTG 50mg QDDRV 800 mg + RTV 100 mg QDExtension DTG 50 mg
Suicide attemptPsychiatric disorders3/2420/2421/123
AsthmaRespiratory, thoracic and mediastinal disorders2/2420/2420/123
Back injuryInjury, poisoning and procedural complications0/2420/2421/123
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2420/2421/123
MethaemoglobinaemiaBlood and lymphatic system disorders0/2420/2421/123
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2421/2420/123
Acute hepatitis CInfections and infestations1/2421/2420/123
ArthralgiaMusculoskeletal and connective tissue disorders1/2421/2420/123
DepressionPsychiatric disorders1/2421/2420/123
Abdominal adhesionsGastrointestinal disorders1/2420/2420/123
Most frequent other events
Showing 10 of 614
Most frequent other events
EventDTG 50mg QDDRV 800 mg + RTV 100 mg QDExtension DTG 50 mg
DiarrhoeaGastrointestinal disorders43/24274/2422/123
NauseaGastrointestinal disorders40/24248/2422/123
HeadacheNervous system disorders40/24226/2422/123
Upper respiratory tract infectionInfections and infestations16/24227/2421/123
Viral upper respiratory tract infectionInfections and infestations26/24224/2425/123
CoughRespiratory, thoracic and mediastinal disorders18/24219/2421/123
InsomniaPsychiatric disorders19/24216/2421/123
VomitingGastrointestinal disorders15/24217/2420/123
Back painMusculoskeletal and connective tissue disorders14/24217/2420/123
RashSkin and subcutaneous tissue disorders13/24217/2420/123

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DTG 50 mg QDDRV 800 mg + RTV 100 mg QDTotal
Mean35.7 ± 10.6636.2 ± 10.6435.9 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)DTG 50 mg QDDRV 800 mg + RTV 100 mg QDTotal
Female314172
Male211201412
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG 50 mg QDDRV 800 mg + RTV 100 mg QDTotal
African American/African Heritage6053113
American Indian or Alaska Native3912
Asian - Central/South Asian Heritage011
Asian - Japanese Heritage101
Asian - South East Asian Heritage101
Native Hawaiian or other Pacific Islander202
White - Arabic/North African Heritage437
White - White/Caucasian/European Heritage169173342
Mixed Race134
Missing101
08

Study locations

66 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Norwalk, Connecticut 06851, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32117, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Vero Beach, Florida 32690, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157-1042, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Dallas, Texas 75204, United States
  • GSK Investigational Site
    Dallas, Texas 75219, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Montpellier Cedex 5, 34295, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Paris Cedex 10, 75475, France
  • GSK Investigational Site
    Paris Cedex 20, 75970, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Saint Denis Cedex 01, 93205, France
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Modena, Emilia-Romagna 41150, Italy
  • GSK Investigational Site
    Roma, Lazio 00149, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Torino, Piemonte 10149, Italy
  • GSK Investigational Site
    Ponce, 00717, Puerto Rico
  • GSK Investigational Site
    San Juan, 00909, Puerto Rico
  • GSK Investigational Site
    San Juan, Puerto Rico
  • GSK Investigational Site
    Bucharest, 021105, Romania
  • GSK Investigational Site
    Bucharest, 030303, Romania
  • GSK Investigational Site
    Constanta, 900708, Romania
  • GSK Investigational Site
    Krasnodar, 350015, Russian Federation
  • GSK Investigational Site
    Moscow, 105275, Russian Federation
  • GSK Investigational Site
    Saratov, 410009, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Volgograd, 400040, Russian Federation
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Bern, 3010, Switzerland
  • GSK Investigational Site
    Lausanne, 1011, Switzerland
  • GSK Investigational Site
    Zurich, CH-8091, Switzerland
09

References and documents

Publications

  • Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. Erratum In: Lancet HIV. 2015 Apr;2(4):e126. PubMed 26424673 ↗
  • Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Erratum In: Lancet. 2015 Jun 27;385(9987):2576. doi: 10.1016/S0140-6736(15)61159-X. PubMed 24698485 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Apr 2013, 17 months.

Results were first posted in Mar 2014, 11 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 33. This study's 17 months is below that.

Counting every sponsor, half of 75 studies reached it within 30 months; a quarter within 17 and three quarters within 53.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 10, 2011
StartActual
Oct 31, 2011
Primary completionActual
Apr 22, 2013
CompletionActual
Dec 26, 2016
Results first posted
Mar 27, 2014
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01449929
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 10, 2011
Start date
Oct 31, 2011
Primary completion
Apr 22, 2013
Completion
Dec 26, 2016
Results posted
Mar 27, 2014
Last update
Jan 16, 2018

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion